HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).

Inclusion Criteria:

1. The patient fully understands this study, voluntarily participates, and signs the informed consent form (ICF);
2. Age ≥18 years;
3. Newly diagnosed with MPAL according to the World Health Organization (WHO) 2022 classification.
4. The patient has not started anti-leukemia treatment after the initial diagnosis (except cytoreductive therapy, such as hydroxyurea or cytarabine \<1.0 g/day or glucocorticoids);
5. Expected survival ≥12 weeks;
6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
7. Normal cardiac function, left ventricular ejection fraction ≥50%; normal renal function: creatinine clearance ≥30 ml/min; normal liver function: ALT \<5 times the normal value, bilirubin \<3 times the normal value;

Exclusion Criteria:

1. Patients who have had or currently have other malignant tumors requiring treatment;
2. Patients with central nervous system (CNS) infiltration;
3. Other clinically significant uncontrolled conditions, including but not limited to: (1) uncontrolled or active systemic infections (viral, bacterial, or fungal); (2) chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) requiring treatment; (3) uncontrolled hypertension, etc.;
4. Patients who cannot take oral medications or have malabsorption syndrome;
5. Patients with a known history of immediate or delayed hypersensitivity reactions to drugs of the same class as the study medication or to excipients;
6. Pregnant or breastfeeding women, or patients who refuse to use effective contraception during the study;
7. Patients with a history of severe neurological or psychiatric disorders who cannot understand or comply with the study protocol;
8. Patients with severe heart disease, such as myocardial infarction, severe or unstable angina, severe arrhythmias;
9. Patients known to be infected with human immunodeficiency virus (HIV); patients with active hepatitis B or C; subjects who are inactive hepatitis carriers or whose viral hepatitis titers are low after treatment with non-prohibited antiviral drugs are not excluded;
10. Patients who cannot take oral medications or have malabsorption syndrome;
11. Patients whom the investigator determines are unsuitable to participate in this study.